Terns Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Terns Pharmaceuticals's earnings have been declining at an average annual rate of -21.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 12.3% per year.
Key information
-21.2%
Earnings growth rate
118.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -12.3% |
| Return on equity | -24.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Terns Pharmaceuticals: Another Potential GLP-1 Entrant
Oct 21Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Sep 25Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive
Sep 10We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Aug 18
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
May 03Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Jan 12We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Sep 29Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Jun 06Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Feb 21Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Oct 03Terns Pharmaceuticals: The Easy Money Has Been Made
Sep 20Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08
Aug 08Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?
Jun 14Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Mar 16We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Nov 24We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Aug 24Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study
Jun 14Revenue & Expenses Breakdown
How Terns Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -88 | 30 | 70 |
| 30 Jun 24 | 0 | -96 | 39 | 69 |
| 31 Mar 24 | 0 | -91 | 39 | 65 |
| 31 Dec 23 | 0 | -90 | 39 | 63 |
| 30 Sep 23 | 0 | -85 | 39 | 57 |
| 30 Jun 23 | 0 | -72 | 25 | 54 |
| 31 Mar 23 | 0 | -68 | 24 | 49 |
| 31 Dec 22 | 0 | -60 | 22 | 40 |
| 30 Sep 22 | 1 | -59 | 22 | 38 |
| 30 Jun 22 | 1 | -54 | 21 | 33 |
| 31 Mar 22 | 1 | -51 | 21 | 31 |
| 31 Dec 21 | 1 | -50 | 20 | 31 |
| 30 Sep 21 | 0 | -35 | 15 | 30 |
| 30 Jun 21 | 0 | -35 | 14 | 28 |
| 31 Mar 21 | 0 | -34 | 11 | 30 |
| 31 Dec 20 | 0 | -29 | 9 | 28 |
| 30 Sep 20 | 0 | -40 | 10 | -7 |
| 31 Dec 19 | 0 | -69 | 9 | 27 |
Quality Earnings: TERN is currently unprofitable.
Growing Profit Margin: TERN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TERN is unprofitable, and losses have increased over the past 5 years at a rate of 21.2% per year.
Accelerating Growth: Unable to compare TERN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TERN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42%).
Return on Equity
High ROE: TERN has a negative Return on Equity (-24.16%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 22:44 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Terns Pharmaceuticals, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Corinne Johnson | Goldman Sachs |
| Corinne Johnson | Goldman Sachs |